Literature DB >> 11472585

Plasma and liver carnitine status of children with chronic liver disease and cirrhosis.

M A Selimoglu1, S Aydogdu, R V Yagci, A Huseyinov.   

Abstract

BACKGROUND: Carnitine is an essential cofactor in the transfer of long-chain fatty acids across the inner mitochondrial membrane for oxidation. As its synthesis is performed in the liver, alterations in carnitine metabolism is expected in liver diseases, especially in cirrhosis.
METHODS: In this study, we investigated plasma and liver carnitine concentrations of 68 children with chronic liver disease, 36 of whom had cirrhosis as well. Carnitine level was determined by enzymatic method.
RESULTS: Plasma and liver carnitine concentrations were not correlated. Mean plasma carnitine level of cirrhotic children was significantly lower than that of the control group (P<0. 0001). While there was no difference between liver carnitine concentrations of children with chronic liver disease and cirrhosis (P>0.05), mean plasma level of cirrhotics were lower (P<0.05). Plasma carnitine was correlated with albumin, triglyceride and gamma glutamyl transpeptidase (GGT) in patients with chronic liver disease (P<0.05). Liver carnitine was correlated with GGT in cirrhotic patients (P<0.005). Children with malnutrition had higher plasma and liver carnitine levels (P<0.05). The highest plasma and liver carnitine levels were detected in children with biliary atresia and criptogenic cirrhosis, respectively. Both the lowest plasma and liver carnitine levels were detected in Wilson's disease.
CONCLUSION: Children with cirrhosis have low plasma carnitine concentrations. This finding is prominent in children with Wilson's disease. As carnitine is an essential factor in lipid metabolism, the carnitine supplementation for patients with cirrhosis in childhood, especially with Wilson's disease, seems to be mandatory.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11472585     DOI: 10.1046/j.1442-200x.2001.01423.x

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  5 in total

1.  Acetyl-L-carnitine for patients with hepatic encephalopathy.

Authors:  Arturo J Martí-Carvajal; Christian Gluud; Ingrid Arevalo-Rodriguez; Cristina Elena Martí-Amarista
Journal:  Cochrane Database Syst Rev       Date:  2019-01-05

2.  Effects on the Human Body of a Dietary Supplement Containing L-Carnitine and Garcinia cambogia Extract: A Study using Double-blind Tests.

Authors:  Yoshikazu Yonei; Yoko Takahashi; Sawako Hibino; Miwako Watanabe; Toshito Yoshioka
Journal:  J Clin Biochem Nutr       Date:  2008-03       Impact factor: 3.114

3.  Identification of the plasma metabolomics as early diagnostic markers between biliary atresia and neonatal hepatitis syndrome.

Authors:  Dongying Zhao; Lianshu Han; Zhengjuan He; Jun Zhang; Yongjun Zhang
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

Review 4.  The Importance of the Fatty Acid Transporter L-Carnitine in Non-Alcoholic Fatty Liver Disease (NAFLD).

Authors:  Dragana Savic; Leanne Hodson; Stefan Neubauer; Michael Pavlides
Journal:  Nutrients       Date:  2020-07-22       Impact factor: 5.717

Review 5.  Membrane transporters in a human genome-scale metabolic knowledgebase and their implications for disease.

Authors:  Swagatika Sahoo; Maike K Aurich; Jon J Jonsson; Ines Thiele
Journal:  Front Physiol       Date:  2014-03-11       Impact factor: 4.566

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.